罕见种系变异与前列腺癌根治性治疗后快速生化复发相关:泛前列腺癌研究组研究
该研究分析850例接受根治性治疗的前列腺癌患者血液DNA全基因组测序数据,鉴定15822个罕见预测有害编码种系突变,用Cox回归模型按功能注释基因集预测生化复发时间,并在TCGA数据集383例患者中验证。PI3K/AKT/mTOR、炎症反应和KRAS信号(上调)基因集的罕见变异与生化复发时间改变显著相关,缺氧基因集在TCGA独立数据集中得到验证。
要点
- 罕见预测有害种系变异在Hallmark基因集中与根治性治疗后生化复发时间改变一致相关。
- PI3K/AKT/mTOR、炎症反应和KRAS信号(上调)基因集在全样本中与风险升高结局显著相关。
- 缺氧基因集在独立TCGA数据集中得到验证,诊断时种系检测可能有助于分层临床决策。
核心结论
- 首次证明罕见有害编码种系变异与根治性治疗后生化复发时间稳健相关,并包含队列独立验证。
- 作者认为诊断时种系检测可通过分层患者进行差异化临床管理来辅助临床决策。
研究设计与样本
- 对来自英国、加拿大、德国、澳大利亚和法国的泛前列腺癌研究组(PPCG)联盟850例接受根治性治疗的前列腺癌患者血液DNA全基因组测序数据进行分析。
- 使用癌症基因组图谱(TCGA)数据集的383例患者验证研究发现。
主要发现
- 共鉴定15822个罕见(MAF<1%)预测有害编码种系突变。
- 最佳Cox回归多因素模型显示Hallmark基因集中的罕见预测有害种系变异与生化复发时间改变一致相关。
- 建模所有样本时,PI3K/AKT/mTOR、炎症反应和KRAS信号(上调)三个基因集与风险升高结局有统计学显著关联。
- 在更高分级癌症患者中,PI3K/AKT/mTOR和KRAS信号(上调)以及胰腺β细胞、通过NKFB的TNFA信号和缺氧基因集也相关,其中缺氧基因集在独立TCGA数据集中得到验证。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Germline variants explain more than a third of prostate cancer (PrCa) risk, but very few associations have been identified between heritable factors and clinical progression. OBJECTIVE: To find rare germline variants that predict time to biochemical recurrence (BCR) after radical treatment in men with PrCa and understand the genetic factors associated with such progression. DESIGN, SETTING, AND PARTICIPANTS: Whole-genome sequencing data from blood DNA were analysed for 850 PrCa patients with radical treatment from the Pan Prostate Cancer Group (PPCG) consortium from the UK, Canada, Germany, Australia, and France. Findings were validated using 383 patients from The Cancer Genome Atlas (TCGA) dataset. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A total of 15,822 rare (MAF <1%) predicted-deleterious coding germline mutations were identified. Optimal multifactor and univariate Cox regression models were built to predict time to BCR after radical treatment, using germline variants grouped by functionally annotated gene sets. Models were tested for robustness using bootstrap resampling. RESULTS AND LIMITATIONS: Optimal Cox regression multifactor models showed that rare predicted-deleterious germline variants in "Hallmark" gene sets were consistently associated with altered time to BCR. Three gene sets had a statistically significant association with risk-elevated outcome when modelling all samples: PI3K/AKT/mTOR, Inflammatory response, and KRAS signalling (up). PI3K/AKT/mTOR and KRAS signalling (up) were also associated among patients with higher-grade cancer, as were Pancreas-beta cells, TNFA signalling via NKFB, and Hypoxia, the latter of which was validated in the independent TCGA dataset. CONCLUSIONS: We demonstrate for the first time that rare deleterious coding germline variants robustly associate with time to BCR after radical treatment, including cohort-independent validation. Our findings suggest that germline testing at diagnosis could aid clinical decisions by stratifying patients for differential clinical management. PATIENT SUMMARY: Prostate cancer patients with particular genetic mutations have a higher chance of relapsing after initial radical treatment, potentially providing opportunities to identify patients who might need additional treatments earlier.
引用
- Burns D, Anokian E, Saunders EJ, et al. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. Eur Urol. 2022. PMID: 35659150. doi:10.1016/j.eururo.2022.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。